Free Trial

Exelixis (NASDAQ:EXEL) Given Sector Perform Rating at Royal Bank Of Canada

Exelixis logo with Medical background

Exelixis (NASDAQ:EXEL - Get Free Report)'s stock had its "sector perform" rating reaffirmed by stock analysts at Royal Bank Of Canada in a research report issued to clients and investors on Tuesday, Marketbeat reports. They presently have a $50.00 price target on the biotechnology company's stock, up from their previous price target of $45.00. Royal Bank Of Canada's price objective indicates a potential upside of 11.46% from the company's current price.

EXEL has been the subject of a number of other research reports. Jefferies Financial Group set a $50.00 price objective on Exelixis and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Morgan Stanley reiterated an "overweight" rating and set a $47.00 target price (up previously from $40.00) on shares of Exelixis in a research report on Wednesday, May 14th. Wall Street Zen cut Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. Truist Financial reiterated a "buy" rating and set a $55.00 target price (up previously from $43.00) on shares of Exelixis in a research report on Monday, June 23rd. Finally, Benchmark reiterated a "neutral" rating on shares of Exelixis in a research report on Monday, June 23rd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $44.72.

Check Out Our Latest Stock Report on Exelixis

Exelixis Trading Down 0.7%

Exelixis stock traded down $0.31 during mid-day trading on Tuesday, hitting $44.86. The stock had a trading volume of 2,063,340 shares, compared to its average volume of 2,521,006. Exelixis has a one year low of $22.20 and a one year high of $49.62. The firm has a market capitalization of $12.23 billion, a P/E ratio of 20.39, a P/E/G ratio of 0.91 and a beta of 0.28. The firm's 50 day moving average is $42.42 and its 200 day moving average is $38.03.

Insider Buying and Selling at Exelixis

In other news, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $45.47, for a total value of $3,309,124.72. Following the completion of the transaction, the chief marketing officer owned 465,393 shares in the company, valued at approximately $21,161,419.71. The trade was a 13.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stelios Papadopoulos sold 36,508 shares of Exelixis stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $44.35, for a total value of $1,619,129.80. Following the completion of the transaction, the director owned 1,279,416 shares of the company's stock, valued at approximately $56,742,099.60. This trade represents a 2.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 458,113 shares of company stock worth $21,024,817 over the last three months. 2.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Exelixis

A number of institutional investors and hedge funds have recently modified their holdings of EXEL. Steward Partners Investment Advisory LLC boosted its holdings in shares of Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after purchasing an additional 330 shares during the period. Proficio Capital Partners LLC purchased a new position in shares of Exelixis in the 4th quarter worth approximately $706,000. Raymond James Financial Inc. purchased a new position in shares of Exelixis in the 4th quarter worth approximately $17,046,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Exelixis in the 4th quarter worth approximately $240,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Exelixis by 5.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 63,447 shares of the biotechnology company's stock worth $2,113,000 after purchasing an additional 3,349 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Company Profile

(Get Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Featured Articles

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Should You Invest $1,000 in Exelixis Right Now?

Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines